Pharma firm Boehringer Ingelheim has brought in OgilvyHealthPR as the global comms agency for its Pradaxa drug, which prevents blood clotting.
OHPR won the account following a competitive pitch. Pradaxa is an oral anticoagulant, used to prevent and treat acute and chronic thromboembolic disease.
OHPR will work with sister company Ogilvy Healthworld Digital to dev elop and implement an integrated comms programme. Ogilvy Healthworld Digital is headed up by managing partners Caroline Howe and David Davenport-Firth. The account will be led out of London by Deanne Wallace.
Pradaxa is currently used in more than 50 countries for primary prevention of venous thromboembolic occurrences in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. It is also being investigated for the prevention of stroke in pat ients with atrial fibrillation (abnormal heart rhythm).
OHPR already works on other global accounts with Boehringer Ingelheim, including its diabetes portfolio, and has appointed of Ben Fisher as associate director on these brands. Fisher has ten years’ experience in healthcare comms and joins from Porter Novelli where he was an account director.
in addition to heading up the Boehringer diabetes portfolio, Ben will also focus on new business.